ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Kevin D Courtney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.